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Previewsleukemic cells (Reynaud et al., 2011).
Could this cytokine also transform the
function of the normal HSPCs? Consistent
with the different effects of the leukemic
cells on normal HSCs and progenitors,
expression of the IL-6 receptor was found
to bemuch higher in the latter. The authors
went on to perform loss-of-function exper-
iments using IL-6 blocking antibodies and
an inducible Mx1-Cre;IL-6Raflox/flox sys-
tem. Both the pharmacological blockade
and genetic deletion experiments showed
a complete yet transient phenotypic rever-
sion in leukemic-exposed hematopoietic
progenitors. Reduced IL-6 production
and rescue of the induced leukemic-
like phenotypes were also observed in
chimeric mice treated with imatinib, the
tyrosine-kinase inhibitor currently used to
treat CML patients.
To address the relevance to human dis-
ease, Welner et al. (2015) cultured adult
bone marrow CD34+ cells mixed with
bone marrow from either healthy subjects
or CML patients, obtaining similar results
as in the mouse model, i.e., increased
IL-6 content and CD34+ cell proliferation,
but decreased lymphoid production.
These phenotypes were also reverted by
IL-6 inhibition.
A recent study has shown that both the
mutated and non-mutated leukemic-
exposed hematopoietic cells produce in-
flammatory cytokines in MPN (Kleppe
et al., 2015). This study found IL-6 to bemainly secreted by the mutated cells.
Although the mutations explored in the
Welner et al. (2015) study and the Kleppe
et al. (2015) study are different, parallels
from both studies point toward a scenario
in which IL-6 secretion by mutant cells
transforms normal hematopoietic cells
into leukemic-like cells.
In summary, several alterations of
normal bone marrow cells induced by
mutated HSPCs are required for the
manifestation and progression of MPN
(Figure 1): (1) neuroglial damage in the
bone marrow and induced apoptosis of
HSC-niche forming nestin+ MSC, leading
to uncontrolled proliferation of mutated
HSCs (Arranzetal., 2014); (2)productionof
pro-inflammatory cytokines by leukemic
and normal cells (Reynaud et al., 2011;
Kleppe et al., 2015); (3) induction of some
leukemic-like features in the normal he-
matopoietic progenitors (Welner et al.,
2015); and (4) excessive proliferation of
osteoblastic precursors that become less
supportive for hematopoietic progenitors
(Krause et al., 2013; Schepers et al., 2013).
Targeting the non-mutated bone
marrow cells therefore opens up an
attractive door for the development of
new therapeutic strategies.REFERENCES
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Ependymomas have a variable prognosis. In this issue of Cancer Cell, Pajtler and colleagues identify nine
subgroups of ependymoma using DNA methylation profiles. Two subgroups, predominately pediatric, are
responsible for most of the mortality, with all others having nearly 100% overall survival after 5 years.For the past several decades, there has
been little progress in the treatment of
ependymomas. Currently, treatment islargely restricted to maximal surgical
resection and, in some cases, external
beam radiation. The tumors do not con-sistently respond to chemotherapy, and
clinical behavior is not accurately pre-
dicted by histologic grade. Currentl 27, May 11, 2015 ª2015 Elsevier Inc. 613
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Previewshistologic criteria divide the tumors into
grade I subependymomas or myxopapil-
lary ependymomas, grade II ependymo-
mas, and grade III anaplastic ependymo-
mas. Grade II ependymomas are the
most common ependymomas and are
further subdivided into cellular, papillary,
clear cell, and tancytic (Korshunov et al.,
2010). These subgroupings are imprecise
and, to a degree, subjective, limiting
their usefulness in treatment decision
making.
In this issue of Cancer Cell, Pajtler et al.
(2015) address these challenges using
DNA methylation profiling to test the
largest ependymoma cohort studied to
date. Their approach is made possible by
methods that enabled them to acquire
high quality data from formalin fixed
paraffin embedded tumor tissue, allowing
them to perform DNAmethylation profiling
on 500 samples from 12 institutions. Tech-
nologies to monitor DNA methylation pat-
terns are emerging as an important new
approach for cancer classification (Hoves-
tadt et al., 2014). DNA ismethylated during
development at cell fate decisions to
forever alter gene expression in the cell
and its daughters. These patterns reflect
both cell-of-origin and etiology of the dis-
ease. DNA is methylated at cytosine resi-
dues andCpG islands by DNAmethylation
transferase enzymes. DNA methylation
marks are inherited and copied through
every round of cell division by DNMT1 or
can be dynamically modified by so called
de novo methyltransfersases such as
DNMT3A/B. Hypermethylation leads to
inactive heterochromatin and this gener-
ally leads to an irreversible repressive
state, such as during X chromosome inac-
tivation and differentiation (Robertson,
2005). Because DNA methylation marks
are so durable, they can be recovered
from small amounts of DNA stored over
years in formalin fixed paraffin embedded
tissue or in frozen tumor samples with
RNA degradation.
Tumor samples from all CNS compart-
ments are examined, including the spinal
(SP), posterior fossa (PF), and supraten-
torial (ST) regions. Using unsupervised
hierarchical clustering, they show that
tumors in each CNS compartment are
comprised of three subgroups, which
mostly correspond to histology. Spinal
cord tumors included subependymoma
(SP-SE), myxopapillary (SP-MPE), and
anaplastic ependymoma (SP-EPN). Mu-614 Cancer Cell 27, May 11, 2015 ª2015 Elstations in the gene linked to neurofibro-
matosis type 2 (NF2) or deletions of the
NF2 locus on chromosome 22q, previ-
ously associated with spinal cord epen-
dymomas, were limited to the SP-EPN
subgroup.
Posterior fossa ependymoma sub-
groups include subependymoma (PF-SE)
and previously described subtypes A and
B (Archer and Pomeroy, 2011; Witt et al.,
2011), here named PF-EPN-A and PF-
EPN-B. PF-EPN-A tumors, the largest of
the ependymoma subgroups comprising
nearly 50% of all cases, have a stable
genome, are CIMP-positive, and have a
remarkably poor outcome. PF-EPN-B has
the most unstable genome of all ependy-
momas profiled here, with many DNA
copy number gains and losses most often
of whole chromosomes.
Supratentorial tumors are divided
into subependymoma (ST-SE) and two
subgroups characterized by molecular
fusions. The largest supratentorial sub-
group, ST-EPN-RELA, which has excep-
tionally poor prognosis, is characterized
by expression of C11orf95-RELA fusion
transcripts, shown in earlier work to
occur in supratentorial ependymomas
and to be sufficient for oncogenesis
when expressed in stem cells (Parker
et al., 2014). These fusions are hypothe-
sized to activate NF-kB signaling. Inter-
estingly, within this subgroup, a novel
PTEN-TAS2R1 fusion transcript was
found in a RELA fusion negative tumor,
hypothesized to activate NF-kB through
loss of PTEN activity which activates the
Akt/mTOR pathway.
In earlier work, CDKN2A/B homozy-
gous deletion had been shown to corre-
late with poor prognosis of supratentorial
ependymomas (Korshunov et al., 2010).
Here, Pajtler et al. (2015) show that these
events occur exclusively in the RELA sub-
group. It is not yet clear whether the
CDKN2A changes themselves drive poor
outcome or whether they just correlate
with the poor outcome ST-EPN-RELA
group at large. The ST-EPN-RELA sub-
group also has the most copy number
abnormalities of tumors in this compart-
ment, including loss of chr9/9q and
chr11, and is the only subgroup with evi-
dence of chromothripsis among the
supratentorial subgroups.
Finally, YAP1 fusions, primarily YAP1-
MAMLD1, described previously charac-
terize ST-EPN-YAP1, the third supraten-evier Inc.torial subgroup. It is not clear how this
fusion drives tumor growth, although
MAMLD1 and MAML2, both members of
the Mastermind gene family, are known
co-activators of NOTCH. A novel YAP1
fusion is described, where the c-terminus
trans-activating domain of YAP1 is ex-
changed for the FAM118B protein coding
region. YAP1 is a member of the tumor
suppressor hippo pathway that regulates
cell growth, contact inhibition, apoptosis,
and differentiation (Fernandez-L and Ken-
ney, 2010). YAP1 acts downstream of
SHH to regulate proliferation of granule
cells during cerebellar development. It is
not known how these YAP1-truncating fu-
sions drive tumor growth, but YAP1 has
been implicated in a variety of cancer
phenotypes (Fernandez-L and Kenney,
2010).
The two most common subgroups,
PF-EPN-A and ST-EPN-RELA, together
comprise over 65% of all cases and, by
a large margin, have the worst prognosis
(Figure 1). These tumors tend to affect
young patients, and they are remarkably
resistant to treatment. Equally remark-
able, patients in the other subgroups
have an excellent prognosis—nearly all
have close to 100% overall survival after
5 years, which holds true even if the tu-
mors recur.
If validated in an independent cohort,
these findings argue for a change in the
current approach to risk stratification and
treatment. Molecular subtyping proved to
be more accurate for predicting outcome
than histological grading. Multivariate
analysis demonstrated molecular sub-
group, degree of surgical resection, and
gain of 1q as independent prognostic pa-
rameters. After optimal surgical resection,
molecular subtyping should be considered
in treatment decisions, and PF-EPN-A and
ST-EPN-RELA especially should be tar-
geted for the development of novel ap-
proaches given the identification of these
subgroups with extremely poor prognosis
despite aggressive therapy.
This comprehensive survey of the land-
scape of ependymomas creates new op-
portunities to improve clinical care by
more accurate risk stratification. It also
exposes many challenges for the field
and raises new questions. Two molecu-
larly defined subgroups, PF-EPN-A and
ST-EPN-RELA, emerge as the principal
causes of poor outcome. Although they
are responsible for the majority of deaths,
M e d i a n  a g e  a t  d i a g n o s i s  ( y e a r s )  
SP-SE 
1% 
SP-MPE 
5% 
SP-EPN 
4% PF-SE 7% 
PF-EPN-A 
48% 
PF-EPN-B 
10% 
ST-SE 
4% 
ST-EPN-
YAP1 
3% 
ST-EPN-
RELA 
18% 
A 
B 
Spine  
SP- 
Posterior Fossa  
PF- 
Supratentorial  
ST- 
SP-
SE 
SP-
MPE 
SP-
EPN 
PF-
SE 
PF-
EPN-
A 
PF-
EPN-
B 
ST-
SE 
ST-
EPN-
YAP 
ST-
EPN-
REL
A 
49 32 41 59 3 30 40 1.4 8 
S
ur
vi
va
l f
iv
e 
ye
ar
s 100% 
50% 
Figure 1. The Two Largest Subgroups of Ependymoma Have the Lowest Overall 5-Year
Survival Rates and Are Predominantly Pediatric
(A) The overall 5-year survival rates of each subtype are listed as a bar graph. Ependymomas develop in
each compartment of the CNS, spine (SP), posterior fossa (PF), and supratenorial (ST), and each compart-
ment has three subtypes of ependymoma. Median age at diagnosis is listed for each subgroup.
(B) The frequency of patients in each subgroups of ependymoma as identified in the Pajtler et al. (2015)
cohort. PF-EPN-A and ST-EPN-RELA are the most common subtypes of ependymoma.
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Previewsthe mechanisms of their resistance to
treatment remain unclear. They share
similar gene set pathway enrichments:
cell cycle, cell migration, and MAPK
signaling. These two subgroups also share
chromosome 1q gain, which also indepen-
dently predicts poor outcome. Will they
respond to a similar targeted drug ther-
apy? Faithful models of these subgroupsare lacking. Molecular mechanisms of
oncogenesis will need to be defined. Tar-
geting epigenetic modifiers has been sug-
gested as a therapeutic target because of
the similar DNAmethylation patterns of the
worst prognosis tumors (Mack et al.,
2014). There is much to do before we
can begin to make any meaningful prog-
ress to improve the outcome of theseCancer Celtreatment-resistant tumors. The tumor
subgroups with good prognosis are often
treated with external beam radiation,
which hasmany long-term consequences,
including neurocognitive deficits and
increased risk of stroke and second can-
cers. All ependymoma subgroups are
also resistant to conventional chemo-
therapy. Molecular mechanisms that can
be targeted will need to be defined so
that radiation can be eliminated for those
who need treatment after surgery. Defining
the disease landscape is a major step for-
ward, and it highlights the challenges
ahead aswework to improve the outcome
of this devastating disease.REFERENCES
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